# Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

> **NCT00473460** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 1404 (actual)

## Conditions studied

- Lung Diseases
- Bronchitis, Chronic

## Interventions

- **DRUG:** Avelox (Moxifloxacin, BAY12-8039)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00473460
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 1404 (ACTUAL)
- **Last updated:** 2014-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00473460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00473460, "Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00473460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*